Breaking the 'Undruggable' Barrier: Pyrotech Therapeutics' GSDMD Inhibitor Project Receives Clinical Trial Approval

Beijing-based Pyrotech Therapeutics Co., Ltd. announced on August 4, 2026, that its proprietary small-molecule pyroptosis inhibitor PTT-121 has received clinical trial approval from China's National Medical Products Administration (NMPA), paving the way for clinical studies in sepsis and septic shock in China. The program marks the world's first specific GSDMD inhibitor to enter clinical development, challenging the long-held industry consensus that the GSDMD target is "undruggable" and representing a milestone breakthrough in pyroptosis drug development.

Pyroptosis is a form of programmed cell death mediated by Gasdermin proteins. In 2015, a research team led by Shao Feng at the National Institute of Biological Sciences in Beijing published a landmark study in Nature, providing the first molecular-level evidence that GSDMD is the direct executioner protein of pyroptosis. The discovery redefined the core mechanism of pyroptosis and opened an entirely new therapeutic target direction for a broad range of inflammation-related diseases. Sepsis — the proposed indication for PTT-121 — is a life-threatening organ dysfunction caused by a dysregulated host response to infection. The condition progresses rapidly, often triggering a systemic cytokine storm, septic shock, and multi-organ failure within hours, making it a critical emergency in intensive care units. Growing clinical evidence indicates that GSDMD-mediated pyroptosis plays a pivotal role in the onset and progression of sepsis.

GSDMD is a novel pore-forming membrane protein, and there is currently no precedent for drug development targeting pore-forming proteins, nor any established druggability pathway to draw from. Furthermore, GSDMD lacks any enzymatic activity and does not possess a conventional small-molecule binding pocket, leading the industry to widely regard it as an "undruggable" target. Building on the world-class foundational research from Shao Feng's laboratory and leveraging its proprietary drug discovery platform, Pyrotech Therapeutics successfully developed a highly specific, highly potent GSDMD small-molecule inhibitor suitable for intravenous administration. Preclinical data demonstrate that PTT-121 exhibits robust efficacy across multiple sepsis disease models, effectively suppressing cytokine storms and significantly reducing mortality risk in animal models.

The clinical approval of the world's first specific GSDMD inhibitor signifies that the "zero-to-one" basic research achievements in innate immunity and pyroptosis, established by Chinese scientists, have been successfully translated into an innovative therapy directly applicable to ICU critical care scenarios. The development holds the potential to provide a novel therapeutic solution for sepsis treatment, filling a global clinical gap in this field. In the coming years, Pyrotech Therapeutics plans to advance the clinical development of this first-in-class GSDMD inhibitor targeting the pyroptosis pathway, aiming to complete Phase II clinical studies and proof of concept in sepsis and related indications. Meanwhile, a next-generation oral GSDMD inhibitor targeting chronic inflammatory diseases is expected to enter clinical stages in 2027.

The continued advancement of the GSDMD inhibitor program is poised to bring transformative progress to the treatment of pyroptosis-related diseases, while also serving as a landmark achievement in China's original drug development — from basic research to clinical translation — and the full-chain integration of industry, academia, and research.

Pyrotech Therapeutics was co-founded in October 2020 by Academician Shao Feng and Dr. Deng Tianjing, with the mission of becoming a globally leading Chinese biotech company driven by original scientific discoveries made by Chinese scientists. The company's scientific foundation is built on Shao Feng's globally leading biological discoveries in innate immunity and pyroptosis. Focusing on critical unmet medical challenges in inflammation, oncology, central nervous system disorders, and anti-infection, Pyrotech Therapeutics has established a technology platform centered on the "molecular switch of pyroptosis and innate immune regulation." Through in-house research and development and collaborations with leading medical translational institutions in China and abroad, the company is committed to developing revolutionary innovative medicines that bring China's original scientific innovations to patients worldwide.